Cat.	Product	Price	Order
D-1020 SM	25/100 bp mixed DNA ladder	5 €
D-1040 SM	1kb DNA Ladder	5 €
K-2631 SM	AccuPower ProFi Taq PCRpremix	5 €
K-2611 SM	AccuPower PyroHotstart Taq PCR premix	5 €
K-2301 SM	AccuPower Hotstart Pfu peR PreMix	5 €
K-2101 SM	AccuPower RocketScript RTPremix	5 €
K-2501 SM	AccuPower RocketScript RT-PCR premix	5 €
K-6704 SM	AccuPower Dual-HotStart RT-qPCR premix	5 €
K-6251 SM	AccuPower 2X GreenStar qPCRMaster Mix	5 €
K-6210 SM	AccuPower GreenStar qPCR PreMix	5 €
K-6100 SM	AccuPower DualStar qPCR PreMix	5 €

More: AccuPower

AccuPower® ProFi Taq PCR PreMix for high efficiency and amplification of long range PCR.

AccuPower® ProFi Taq PCR PreMix is a convenient lyophilized PCR master mix containing ProFi Taq DNA polymerase, reaction buffer, dNTPs, tracking dye, and a patented stabilizer. ProFi Taq DNA polymerase in the premix is a unique recombinant Taq DNA polymerase that offers enhanced amplification efficiency and higher fidelity for PCR. AccuPower® ProFi Taq PCR PreMix is applicable to any template DNA, and especially effective in amplifying large genomic DNA fragments around 20 kb. AccuPower® ProFi Taq PCR PreMix provides accurate long-range amplification of standard and amplification of low-copy target, and is highly suitable for all PCR applications.

Features and Benefits

Specifications

5' to 3' exonuclease: Yes
3' to 5' exonuclease: Yes
3' – A Overhang: Yes
PCR product size: ~ 30kb

Application

- Primer extension
- long-range amplification from genomic DNA
- High amplification efficiency
- Excellent performance on difficult templates
- Amplification of low-copy targets
- High yield and high sensitivity PCR

Experimental data

Figure 1. Comparison of PCR amplification efficiency between AccuPower® ProFi Taq PCR PreMix from Gentaur and other suppliers' PCR master mix

The cycling conditions for AccuPower® ProFi Taq PCR PreMix were 95°C for 5min, 30 cycles of 95°C for 20 sec, 55°C for 20 sec and 72°C for 30 sec. PCR reactions using other suppliers' PCR master mix were performed according to each supplier's protocol.
Target : human insulin receptor gene.
Lane M : 100 bp DNA Ladder(Gentaur, Cat. No. D-1030)
Lane 1 : 10 ng of human genomic DNA
Lane 2 : 1 ng of human genomic DNA
Lane 3 : 100 pg of human genomic DNA
Lane 4 : 10 pg of human genomic DNA

Figure 2. Comparison of PCR amplification efficiency between AccuPower® ProFi Taq PCR PreMix from Gentaur and other suppliers' PCR master mix

cDNA synthesized from 10-fold serial-diluted human total RNA from 10 ng to 10 pg using AccuPower® RocketScript™ Cycle RT PreMix. (Gentaur, Cat. No K-2201) wase used as a template for PCR amplification. The cycling conditions for AccuPower® ProFi Taq PCR PreMix were 95°C for 5min, 33 cycles of 95°C for 20 sec, 55°C for 20 sec and 72°C for 30 sec. PCR reactions using other suppliers' PCR master mix were performed according to each supplier's protocol.
Target : human GAPDH gene.
Lane M : 100 bp DNA Ladder(Gentaur, Cat. No. D-1030)
Lane 1 : 10 ng of human total cDNA
Lane 2 : 1 ng of human total cDNA
Lane 3 : 100 pg of human total cDNA
Lane 4 : 10 pg of human total cDNA

Figure 3. Comparison of PCR amplification of long targets between AccuPower® ProFi Taq PCR PreMix from Gentaur and other suppliers' PCR master mix

The cycling conditions for AccuPower® ProFi Taq PCR PreMix were 95°C for 5 min, 30 cycles of 95°C for 20 sec, 65°C for 20 sec and 68°C for 4 min. PCR reactions using other suppliers' PCR master mix were performed according to each supplier's protocol.
Lane M1 : Lambda/Hind III marker (Gentaur, Cat. No. D-1050)
Lane M2 : 1 kb DNA Ladder (Gentaur, Cat. No. D-1040)
Lane 1 : 2 kb fragment (human tumor protein p53 gene)
Lane 2 : 3 kb fragment (human tumor protein p53 gene)
Lane 3 : 4.5kb fragment (human DNA cross-link repair 1A gene)
Lane 4 : 8 kb fragment (human hemoglobin epsilon 1 gene)

Figure 4. Comparison of PCR amplification of long targets between AccuPower® ProFi Taq PCR PreMix from Gentaur and other suppliers' PCR master mix

The cycling conditions for AccuPower® ProFi Taq PCR PreMix were 95°C for 5 min, 32 cycles of 95°C for 20 sec and 68°C for 15 min. PCR reactions using other suppliers' PCR master mix were performed according to each supplier's protocol. Human genomic DNA was used as a template for PCR amplification.
Lane M1 : Lambda/Hind III marker (Gentaur, Cat. No. D-1050)
Lane M2 : 1 kb DNA Ladder (Gentaur, Cat. No. D-1040)
Lane 1 : 11 kb fragment
Lane 2 : 13.5 kb fragment
Lane 3 : 17.6 kb fragment
Lane 4 : 21.4 kb fragment

Figure 5. Comparison of PCR amplification of long targets between AccuPower® ProFi Taq PCR PreMix from Gentaur and other suppliers' PCR master mix

The cycling conditions for AccuPower® ProFi Taq PCR PreMix were 95°C for 5 min, 32 cycles of 95°C for 20 sec, 65°C for40 sec, and 68°C for 20 min. PCR reactions using other suppliers' PCR master mix were performed according to each supplier's protocol. Lambda DNA was used as a template for PCR amplification.
Lane M1 : Lambda/Hind III marker (Gentaur, Cat. No. D-1050)
Lane M2 : 1 kb DNA Ladder (Gentaur, Cat. No. D-1040)
Lane 1 : 15 kb fragment
Lane 2 : 20 kb fragment
Lane 3 : 25 kb fragment
Lane 4 : 30 kb fragment

Ready-to-use cocktail containing all components,except primer, for the amplification and detection of DNA in real-time quantitative PCR(qPCR).

The AccuPower® 2X Greenstar qPCR Master Mix is a ready-to-use cocktail containing all components,except primer, for the amplification and detection of DNA in real-time quantitative PCR(qPCR). It combines the automatic "Hotstart" technology of Top DNA polymerase and SYBR Green I fluorescent dye to deliver excellent sensitivity in the quantification of target sequences, with a linear dose response over a wide range of target concentration. Volumes are provided for 100 or 200 amplification reactions of 50ul each.

Features and Benefits

Applications

- Real-time quantification of DNA and cDNA targets
- Gene expression profiling
- Microbial & Viral pathogen detection

Genetically modified organisms can be defined as organisms in which the genetic material (DNA) has been altered intentionally. Technology by which this is achieved is often called recombinant DNA technology, recombinant technology or genetic engineering. This technology allows the transfer of genes from one organism to another, often unrelated - such as insulin and human growth hormone are produced in industrial quantities of yeast - single-celled fungi, which incidentally, is also used in the manufacture of wine, beer, bread, etc. .

Recombinant technology becomes more pervasive in the plant, and hence in refrigerators in each of us. This creates many, absolutely unjustified panic and even hysteria in the community, professionals need to dispel. On the subject, however, to speak and many pseudo experts that only fueled false rumors and myths and incite panic extra.
 
Topic is too broad, so here we only briefly describe the most relevant aspects.

First we point out that genetically modified foods are not mass produced because scientists or even farmers love to experiment with crops, but because they have serious economic benefits. This most often increased resistance to pests, increase yields, reduced need for irrigation and / or fertilization compared to current varieties, or some combination of these qualities. Simply put, the plants are imported genes that give them resistance to pests, herbicides, drought etc.. This increases yields significantly reduces the cost of farmers. In fact, the root cause for the introduction of recombinant technology in plants is notably increasing their resistance to parasites and viral diseases.

Many "experts" speak, often in the media, totally unprepared and totally unaware of the nature of the issue, as repeating ridiculous slogans such as "No mutants in the soup."
 
What many do not realize is that every plant food, used by XIX century, is genetically modified. Plum, for example, is a type that does not exist in nature - it is created by crossing the wild plums and sloes. Melons are types created by polyploidization (technique in biotechnology that will clarify this). The wheat we eat every day in the form of daily bread is not created by nature and man the crossing of wild species.

Many people seem to be afraid of the sound of the word mutant, but it's nothing terrible. It comes from the Latin mutatio, monstrosity does not mean, as many people probably think and change. Mutant mean modified organism, not a freak. In this sense, genetic engineering changes the plants (including those used for food) to make them better - more productive, more stable, etc. Without realizing it, people are engaged in genetic engineering since the dawn of civilization - and cross picking out certain individuals, they received new breeds and varieties in which a certain quality is selectively enhanced - production at chicken or the department of dairy cows crop yield etc. It is to the latter, for example, was established wheat, which is obtained by complex crosses of several plant species. Thus, the person creates something that nature could not create. In essence, the process of creating new plants through cross from the growers do not differ in anything from the analogous process in the laboratory. Nobody refuses melons, watermelons, bread and plum because not exist in nature and man-made "mutants". Why not give the new "genetically modified" foods? In the laboratory, scientists months can achieve results that would have taken decades of growers to be reached. Recombinant technologies also provide a number of completely new features that are unavailable through classical breeding and selection of animals or plants.

For those who are still concerned about the presence of "mutants" on the shelves of supermarkets will clarify that food produced by biotechnology, pass more rigorous tests created a "traditional" - by crossing plants, selecting at high yield, etc. This is not the most appropriate solution because the two slightly different techniques and is much more likely with "traditional" method to create dangerous foods to be noticed than those to be created by means of biotechnological and reach supermarkets. Also, any kind of new biotech pass rigorous tests for toxicity, allergenicity, nutritional changes due to mutation, unforeseen health effects due to mutation and others.

Some will point out this time somewhat appropriate that they can be obtained changes that make some people allergic to one food or another. It really is. But not all the new foods are tested for allergenicity? He is allergic to them, just not to consume them as people who are allergic to strawberries, do not eat them. The fact that some people are allergic to strawberries does not mean that strawberries should be banned for everyone. The same goes for GM foods.

For the first time scientists have deciphered the DNA of flat worms, which may reveal new therapeutic targets for future drugs. The genome is a new resource and the path to faster development of new drugs are urgently needed - flat worms cause two of the seventeen "neglected" tropical diseases listed by the World Health Organization - echinococcosis and cysticercosis.

The research team determined the DNA sequence of the four types of tapeworms to better study the biology and genetics of intestinal parasites. In most species, adults cause few complaints while in the intestines. The larvae, however, can cause serious medical complications in moving their body. They form cysts in the bodies of humans and animals, which can lead to complications such as blindness or epilepsy.

According to Dr. Matthew Beriman of the Wellcome Trust Sanger Institute, parasitosis of flat worms are widespread. Their global burden is comparable to that of multiple sclerosis and melanoma.

Typically, the researchers analyzed the DNA of pathogens and compare it with that of man, and thus identify potential targets for future drugs. In this study, however, researchers are mainly interested in the similarities in the DNA of human intestinal parasites. This is because unlike most pathogens such as bacteria and viruses, flat worms are eukaryotic organisms like humans. Flatworms much more like a human structure and physiology of any bacteria or virus.

Furthermore, by analyzing the similarities between the genomes, researchers discovered which of already existing drugs might be effective against parasites. This can save hundreds of decades of work and millions of dollars in investments.

It turns out that some tapeworms are sensitive to the drugs currently used to treat cancer. Another potential solution is cholesterol lowering medication. In the course of evolution, flat worms have lost the ability to synthesize their own cholesterol, which obtain at the expense of the host. Promising target for new drugs are proteins, through which the larvae absorb cholesterol from the intestine. If the function of these proteins has been crossed, the larvae will stop development and will die.

According to a report published in the Annals of Oncology, women with Herr-2 positive breast cancer who received trastuzumab as adjuvant therapy are at significantly increased risk of metastases in the central nervous system as a first recurrence of the tumor.

According to Dr. Erin Olson, a neurologist at Ohio State University and author of the study, trastuzumab significantly reduced the risk of recurrence, but clinicians should be aware that it increases the risk of them occur in the nervous system. Physicians should carefully monitor patients for neurologic symptoms.

It is suggested that the nervous system is the "refuge" for micro metastatic tumors because trastuzumab does not cross the blood-brain barrier or because tumor cells that do not overexpress Herr-2 receptor migrate more easily into the brain.

In previous studies, Dr. Olson and her team showed that anti Herr-2 targeted therapies increase the frequency of brain metastases. This spurred her to investigate the relationship between brain metastases and trastuzumab. The team analyzed four Phase III clinical trials with a total of 9,020 participants.

Since 4921 women receiving trastuzumab, 125 relapse in the breast (incidence of 2.56%). Of 4099 women who received trastuzumab, 78 relapse of the tumor in the brain (1.94%). In patients treated with trastuzumab treatment brain metastases / total metastases is 16.94 / 100, while those treated with other adjuvant is 8.33 / 100.